Market Overview:
The global organ transplant immunosuppressant drugs market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing incidence of organ failures, rising number of organ transplants, and technological advancements in the field of organ transplantation. The global market for organ transplant immunosuppressant drugs is segmented on the basis of type, application, and region. On the basis of type, it is divided into antibodies, antiproliferative agents, calcineurin inhibitors (CNIs), mTOR inhibitors (mTORIs), and steroids. Antibodies are further classified into monoclonal antibodies (mAbs) and polyclonal antibodies (pAbs). The antiproliferative agents segment includes cytotoxic agents and non-cytotoxic agents. CNIs are further sub-segmented into cyclosporine A (CsA) and tacrolimus (TAC). mTOR inhibitors include sirolimus (SRL) and everolimus ((EVR)). Steroids are sub-divided into corticosteroids and mineralocorticoid receptor antagonists.
Product Definition:
Organ transplant immunosuppressant drugs are medications that help to keep the body from rejecting a transplanted organ. They work by suppressing the immune system, which helps to keep it from attacking the new organ.
Antibodies:
Antibodies are proteins made by the body to fight against diseases and infections.
1) Immunoglobulins: These are produced in response to an antigen (a protein that stimulates the immune system). The most common antigens are bacteria or viruses. When a foreign substance such as bacteria enters the body, an antibody is produced by the B cells for its destruction.
Antiproliferative Agents:
Antiproliferative agents are used in the treatment of cancer and immunosuppressive drugs for organ transplantation. Antiproliferative agents are also used to treat diseases such as myelodysplastic syndrome, chronic granulomatous disease, acute intermittent porphyria, angioedema (largest volume), primary biliary cholangitis (BRCA-mutated), and multiple myeloma.
Application Insights:
Based on the application, the global organ transplant immunosuppressant drugs market is segmented into bone marrow transplantation, heart transplantation, kidney transplantation, liver transplantation and lung transplants. The bone marrow graft and stem cell therapy segment dominated the overall market in terms of revenue in 2017. This can be attributed to an increase in number of donors with matched or mismatched cells which require a higher dose of steroids to prevent acute rejection as well as chronic graft failure.
The other applications include kidney/pancreas/liver dialysis machines; heart/lung assist devices; liver-only machine; lungs only machine; pancreas-only machine (islet cell replacement); and kidney-only machines (volumetric reduction). These devices are used less frequently due to availability of substitutes such as artificial kidneys for patients who need long term dialysis treatment or a second opinion about potential benefits associated with these procedures should they arise.
Regional Analysis:
North America dominated the global organ transplant immunosuppressant drugs market in 2016. The presence of well-developed healthcare infrastructure, high adoption rate of immunosuppressants among patients undergoing transplants, and rising prevalence of chronic conditions leading to organ failure are some major factors responsible for its large share. In addition, increasing R&D investment by companies and government is expected to drive growth over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to a rise in awareness about organ donation coupled with growing medical tourism industry in emerging countries such as India & China & Japan. Moreover, increasing healthcare expenditure levels by governments along with improving reimbursement scenario will boost demand further over the next eight years.
Growth Factors:
- Increasing incidence of organ transplantation procedures across the globe
- Growing demand for organ transplant immunosuppressant drugs due to rising prevalence of organ failure and other diseases
- Technological advancements in the field of organ transplantation that has led to increased number of successful transplants
- Rising awareness about benefits associated with organ transplants and immunosuppressant drugs among people globally
- Availability of government funding for research and development activities in the field of Organ Transplant Immunosuppressant Drugs
Scope Of The Report
Report Attributes
Report Details
Report Title
Organ Transplant Immunosuppressant Drugs Market Research Report
By Type
Antibodies, Antiproliferative Agents, Calcineurin Inhibitors, mTOR Inhibitors, Steroids
By Application
Bone Marrow Transplant, Heart Transplant, Kidney Transplant, Liver Transplant, Lung Transplant
By Companies
F. Hoffmann-La Roche Ltd., Sanofi, AbbVie, Inc., Allergan plc., Astellas Pharma, Inc., Bristol-Myers Squibb Company, Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Janssen Pharmaceutical, Novartis AG, Pfizer, Inc., Veloxis Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
231
Number of Tables & Figures
162
Customization Available
Yes, the report can be customized as per your need.
Global Organ Transplant Immunosuppressant Drugs Market Report Segments:
The global Organ Transplant Immunosuppressant Drugs market is segmented on the basis of:
Types
Antibodies, Antiproliferative Agents, Calcineurin Inhibitors, mTOR Inhibitors, Steroids
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Bone Marrow Transplant, Heart Transplant, Kidney Transplant, Liver Transplant, Lung Transplant
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- F. Hoffmann-La Roche Ltd.
- Sanofi
- AbbVie, Inc.
- Allergan plc.
- Astellas Pharma, Inc.
- Bristol-Myers Squibb Company
- Hoffmann-La Roche Ltd.
- GlaxoSmithKline plc
- Janssen Pharmaceutical
- Novartis AG
- Pfizer, Inc.
- Veloxis Pharmaceuticals
Highlights of The Organ Transplant Immunosuppressant Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Antibodies
- Antiproliferative Agents
- Calcineurin Inhibitors
- mTOR Inhibitors
- Steroids
- By Application:
- Bone Marrow Transplant
- Heart Transplant
- Kidney Transplant
- Liver Transplant
- Lung Transplant
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Organ Transplant Immunosuppressant Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Organ transplant immunosuppressant drugs are medications that help to prevent the body's immune system from attacking the new organ.
Some of the major players in the organ transplant immunosuppressant drugs market are F. Hoffmann-La Roche Ltd., Sanofi, AbbVie, Inc., Allergan plc., Astellas Pharma, Inc., Bristol-Myers Squibb Company, Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Janssen Pharmaceutical, Novartis AG, Pfizer, Inc., Veloxis Pharmaceuticals.
The organ transplant immunosuppressant drugs market is expected to register a CAGR of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Organ Transplant Immunosuppressant Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Organ Transplant Immunosuppressant Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Organ Transplant Immunosuppressant Drugs Market - Supply Chain
4.5. Global Organ Transplant Immunosuppressant Drugs Market Forecast
4.5.1. Organ Transplant Immunosuppressant Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Organ Transplant Immunosuppressant Drugs Market Size (000 Units) and Y-o-Y Growth
4.5.3. Organ Transplant Immunosuppressant Drugs Market Absolute $ Opportunity
5. Global Organ Transplant Immunosuppressant Drugs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Organ Transplant Immunosuppressant Drugs Market Size and Volume Forecast by Type
5.3.1. Antibodies
5.3.2. Antiproliferative Agents
5.3.3. Calcineurin Inhibitors
5.3.4. mTOR Inhibitors
5.3.5. Steroids
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Organ Transplant Immunosuppressant Drugs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Organ Transplant Immunosuppressant Drugs Market Size and Volume Forecast by Application
6.3.1. Bone Marrow Transplant
6.3.2. Heart Transplant
6.3.3. Kidney Transplant
6.3.4. Liver Transplant
6.3.5. Lung Transplant
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Organ Transplant Immunosuppressant Drugs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Organ Transplant Immunosuppressant Drugs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Organ Transplant Immunosuppressant Drugs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Organ Transplant Immunosuppressant Drugs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Organ Transplant Immunosuppressant Drugs Demand Share Forecast, 2019-2026
9. North America Organ Transplant Immunosuppressant Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Organ Transplant Immunosuppressant Drugs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Organ Transplant Immunosuppressant Drugs Market Size and Volume Forecast by Application
9.4.1. Bone Marrow Transplant
9.4.2. Heart Transplant
9.4.3. Kidney Transplant
9.4.4. Liver Transplant
9.4.5. Lung Transplant
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Organ Transplant Immunosuppressant Drugs Market Size and Volume Forecast by Type
9.7.1. Antibodies
9.7.2. Antiproliferative Agents
9.7.3. Calcineurin Inhibitors
9.7.4. mTOR Inhibitors
9.7.5. Steroids
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Organ Transplant Immunosuppressant Drugs Demand Share Forecast, 2019-2026
10. Latin America Organ Transplant Immunosuppressant Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Organ Transplant Immunosuppressant Drugs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Organ Transplant Immunosuppressant Drugs Market Size and Volume Forecast by Application
10.4.1. Bone Marrow Transplant
10.4.2. Heart Transplant
10.4.3. Kidney Transplant
10.4.4. Liver Transplant
10.4.5. Lung Transplant
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Organ Transplant Immunosuppressant Drugs Market Size and Volume Forecast by Type
10.7.1. Antibodies
10.7.2. Antiproliferative Agents
10.7.3. Calcineurin Inhibitors
10.7.4. mTOR Inhibitors
10.7.5. Steroids
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Organ Transplant Immunosuppressant Drugs Demand Share Forecast, 2019-2026
11. Europe Organ Transplant Immunosuppressant Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Organ Transplant Immunosuppressant Drugs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Organ Transplant Immunosuppressant Drugs Market Size and Volume Forecast by Application
11.4.1. Bone Marrow Transplant
11.4.2. Heart Transplant
11.4.3. Kidney Transplant
11.4.4. Liver Transplant
11.4.5. Lung Transplant
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Organ Transplant Immunosuppressant Drugs Market Size and Volume Forecast by Type
11.7.1. Antibodies
11.7.2. Antiproliferative Agents
11.7.3. Calcineurin Inhibitors
11.7.4. mTOR Inhibitors
11.7.5. Steroids
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Organ Transplant Immunosuppressant Drugs Demand Share, 2019-2026
12. Asia Pacific Organ Transplant Immunosuppressant Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Organ Transplant Immunosuppressant Drugs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Organ Transplant Immunosuppressant Drugs Market Size and Volume Forecast by Application
12.4.1. Bone Marrow Transplant
12.4.2. Heart Transplant
12.4.3. Kidney Transplant
12.4.4. Liver Transplant
12.4.5. Lung Transplant
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Organ Transplant Immunosuppressant Drugs Market Size and Volume Forecast by Type
12.7.1. Antibodies
12.7.2. Antiproliferative Agents
12.7.3. Calcineurin Inhibitors
12.7.4. mTOR Inhibitors
12.7.5. Steroids
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Organ Transplant Immunosuppressant Drugs Demand Share, 2019-2026
13. Middle East & Africa Organ Transplant Immunosuppressant Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Organ Transplant Immunosuppressant Drugs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Organ Transplant Immunosuppressant Drugs Market Size and Volume Forecast by Application
13.4.1. Bone Marrow Transplant
13.4.2. Heart Transplant
13.4.3. Kidney Transplant
13.4.4. Liver Transplant
13.4.5. Lung Transplant
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Organ Transplant Immunosuppressant Drugs Market Size and Volume Forecast by Type
13.7.1. Antibodies
13.7.2. Antiproliferative Agents
13.7.3. Calcineurin Inhibitors
13.7.4. mTOR Inhibitors
13.7.5. Steroids
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Organ Transplant Immunosuppressant Drugs Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Organ Transplant Immunosuppressant Drugs Market: Market Share Analysis
14.2. Organ Transplant Immunosuppressant Drugs Distributors and Customers
14.3. Organ Transplant Immunosuppressant Drugs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. F. Hoffmann-La Roche Ltd.
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Sanofi
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. AbbVie, Inc.
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Allergan plc.
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Astellas Pharma, Inc.
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Bristol-Myers Squibb Company
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Hoffmann-La Roche Ltd.
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. GlaxoSmithKline plc
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Janssen Pharmaceutical
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Novartis AG
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Pfizer, Inc.
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Veloxis Pharmaceuticals
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
&n